Worldwide prevalence, genotype distribution and management of hepatitis C
Acta Gastro Enterologica Belgica · 2021-12 · 84 (4) · 633-652
DOI: 10.51821/84.4.015 ↗At a glance
Übersichtsarbeit in Acta Gastro Enterologica Belgica, 2021-11. Written by P Guntipalli and 14 co-authors. Institution: Division of Clinical and Translational Research, Larkin Community Hospital, South Miami, Florida, United States of America. Major MEDLINE topics: Hepatitis C, Hepatitis C, Chronic, Liver Neoplasms. Cited 42 times so far (Crossref); 187 references.
Abstract (original language)
Hepatitis C virus (HCV) is one of the leading causes of chronic liver disease, cirrhosis, and hepatocellular carcinoma, resulting in major global public health concerns. The HCV infection is unevenly distributed worldwide, with variations in prevalence across and within countries. The studies on molecular epidemiology conducted in several countries provide an essential supplement for a comprehensive knowledge of HCV epidemiology, genotypes, and subtypes, along with providing information on the impact of current and earlier migratory flows. HCV is phylogenetically classified into 8 major genotypes and 57 subtypes. HCV genotype and subtype distribution differ according to geographic origin and transmission risk category. Unless people with HCV infection are detected and treated appropriately, the number of deaths due to the disease will continue to increase. In 2015, 1.75 million new viral infections were mostly due to unsafe healthcare procedures and drug use injections. In the same year, access to direct-acting antivirals was challenging and varied in developing and developed countries, affecting HCV cure rates based on their availability. The World Health Assembly, in 2016, approved a global strategy to achieve the elimination of the HCV public health threat by 2030 (by reducing new infections by 90% and deaths by 65%). Globally, countries are implementing policies and measures to eliminate HCV risk based on their distribution of genotypes and prevalence.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Division of Clinical and Translational Research, Larkin Community Hospital, South Miami, Florida, United States of America.
- Department of Biomedical Sciences and Human Oncology, Unit of Internal Medicine and Clinical Oncology, University of Bari "Aldo Moro", 70124 Bari, Italy.
- Department of Family Medicine, Mississauga Health Centre, Mississauga, Ontario, Canada.
- Department of Mathematics and Natural Sciences, Prince Mohammad Bin Fahad University, Al Khobar, Saudi Arabia.
- Department of Gastroenterology, John Hopkins Hospital, Baltimore, Maryland, USA.
- Advent Health Cancer Institute, Division of Oncology, Orlando, FL 32804, USA.
Cite
APA
Guntipalli, P., Pakala, R., Kumari Gara, S., Ahmed, F., Bhatnagar, A., Endaya Coronel, M. K., Razzack, A. A., Solimando, A. G., Thompson, A., Andrews, K., Enebong Nya, G., Ahmad, S., Ranaldo, R., Cozzolongo, R., & Shahini, E. (2021). Worldwide prevalence, genotype distribution and management of hepatitis C. Acta Gastro Enterologica Belgica, 84(4), 633-652. https://doi.org/10.51821/84.4.015
Vancouver
Guntipalli P, Pakala R, Kumari Gara S, Ahmed F, Bhatnagar A, Endaya Coronel MK, et al. Worldwide prevalence, genotype distribution and management of hepatitis C. Acta Gastro Enterologica Belgica. 2021;84(4):633-652. doi:10.51821/84.4.015
BibTeX
@article{Guntipalli2021,
author = {Guntipalli, P and Pakala, R and Kumari Gara, S and Ahmed, F and Bhatnagar, A and Endaya Coronel, M-K and Razzack, A A and Solimando, A G and Thompson, A and Andrews, K and Enebong Nya, G and Ahmad, S and Ranaldo, R and Cozzolongo, R and Shahini, E},
title = {Worldwide prevalence, genotype distribution and management of hepatitis C},
journal = {Acta Gastro Enterologica Belgica},
year = {2021},
volume = {84},
number = {4},
pages = {633--652},
doi = {10.51821/84.4.015}
}
EUVIMED